According to MedLife representatives, the discussions for this acquisition were initiated at the end of 2019 but were postponed in the context of the Covid 19 pandemic and resumed this year.
Currently, the acquisition of OncoCard Hospital is carried out by Policilnica de Diagnostic Rapid (PDR), the first company acquired by MedLife Group. Once that transaction was completed and PDR integrated within MedLife Group, PDR Brașov had an important evolution, the company soon became one of the top 10 medical operators at national level.
“For more than ten years, we have been bringing together new entrepreneurial doctors from all over the country to develop the Romanian equity. Today, beyond the fact that we managed to develop the largest community of Romanian entrepreneurs in the private medical sector, we are also witnessing a replication of our acquisition strategy at the level of MedLife group subsidiaries. We are very proud of what we have managed to build. It is proof that the strategy we followed, to keep the founding management, to go together and to grow rapidly, was a winning one. And we are convinced that we will be able to replicate this model at regional level as well”, said Mihai Marcu, President & CEO of the MedLife Group
“The contract of OncoCard Hospital acquisition, one of the largest operators in the oncology area at national level, represents our most important achievement, throughout our entire history. I am one of the founders and I am proud to be part of MedLife community of entrepreneurs and to support the development of this ecosystem in the private medical sector”, said Mihai Vârciu, founding doctor of the PDR Brașov Group, part of MedLife Group.
Founded in 2012, OncoCard Hospital is based on an innovative concept of integrative medicine that starts in the diagnostic phase of the oncologic patient and covers the entire period of specific active therapies.
The medical unit includes a specialized outpatient unit, oncology surgery department, hematology, radiotherapy and medical imaging departments, as well as its own laboratory, used internally for inpatients. OncoCard also has state-of-the-art technology that allows high-precision imaging investigations, including PET / CT and scintigraphy, and targeted treatments such as IMRT, RapidArc or conventional threedimensional radiotherapy.
From its opening until now, investments worth 24 million euros have been made in OncoCard Hospital Brasov. In 2020, the company registered a consolidated turnover amounting to 56.4 million lei, increasing by 21% compared to 2019.
“Our mission is to be in the permanent service of our patients and to provide medical services at the highest level of performance, so that we can instill confidence, courage, the desire to fight, to conquer the diseases and to restore life confidence. From the first discussions with MedLife, I was confident that our goals are the same, so I trusted this partnership and continued it. We aim continuously to become a standard of quality in the offered medical services, and together with MedLife we will continue this path, helping more and more patients who need us”, said Raluca Butuza, owner of OncoCard Brasov.
The transaction is going to be analysed by the Competition Council. Once approved, it could become the MedLife Group’s second largest transaction in 2021, after Neolife’s approval.
“As we announced, we have 2-3 more important M&A transactions in progress. We are investing and we aim to enlarge the network in Romania, which is already substantially larger than any other private network, with a much higher coverage at county and Bucharest level. We wish that our subscribers, patients or employees of partner companies to know that they can drive to one of the MedLife medical units within an hour, no matter where they are. At the same time, we want to strengthen our presence outside borders. After more than ten years in which we were a national leader, it is high time to prove that we can become one of the regional leaders as well”, declared Mihai Marcu.